Status and phase
Conditions
Treatments
About
This study will evaluate the safety and tolerability and Aß-specific antibody response of CAD106 in patients with mild to moderate Alzheimer's Disease.
Patients also had a 2 year follow-up to assess disease progression where no drug was administered.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Patients, who are on stable treatment with cholinesterase-inhibitors (ChEIs) and/or memantine for at least 3 months, and/or with SSRIs and/or other newer antidepressants (without anticholinergic properties) for at least 4 weeks before randomization, can be included into the study.
Primary purpose
Allocation
Interventional model
Masking
58 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal